UAEM Evidence

  • SUBMIT
  • About
  • All posts (hover for categories)
    • Access Gap
    • UAEM Basic references
    • Excessive IP
    • Pharma general
    • Patents VS Innovation
    • Research Gap
    • NTDs
    • Trans-Pacific Partnership Agreement
    • Universities vs Industry
    • Patenting living organisms
  • Bookmarklet
A place for all useful evidence to come together.

Category UAEM-authored

How the MDGs gave up on measuring access to medicines

June 6, 2016 · by uaemevidence · in Access Gap, UAEM-authored, Uncategorized · Leave a comment

Recent example of catastrophic licensing of university-invented drug

April 30, 2014 · by uaemevidence · in GAL - examples in practice, UAEM-authored, Universities vs Industry · Leave a comment

Review of secondary patents (prodrugs, polymorphs, salts)

December 3, 2013 · by uaemevidence · in Access Gap, Excessive IP, UAEM-authored · Leave a comment

Tiered-pricing is not a good strategy for improving A2M

December 3, 2013 · by uaemevidence · in Access Gap, UAEM Basic references, UAEM-authored · Leave a comment

The Silent Epidemic of Exclusive University Licensing Policies on Compounds for Neglected Diseases and Beyond

November 9, 2013 · by uaemevidence · in UAEM-authored · Leave a comment

CONTACT

uaemevidence@gmail.com

SEARCH

Categories

  • Access Gap (34)
  • Arguments from Pharma (10)
  • De-linkage examples (3)
  • Excessive IP (16)
  • GAL – examples in practice (2)
  • NTDs (10)
  • Open Science – examples (2)
  • Patenting living organisms (8)
  • Patents VS Innovation (16)
  • Pharma general (31)
  • Pharma in politics (2)
  • Research Gap (14)
  • SRL (3)
  • Trans-Pacific Partnership Agreement (8)
  • TRIPS+ (4)
  • UAEM Basic references (22)
  • UAEM-authored (5)
  • Uncategorized (8)
  • Universities vs Industry (13)

Enter your email address to follow this blog and receive notifications of new posts by email.

Create a free website or blog at WordPress.com.